RadNet's Aidence, Google Health enter collaboration for lung cancer screening
RadNet (NASDAQ:RDNT) reported that its lung artificial intelligence subsidiary, Aidence, and Google Health, a division of Alphabet (GOOG) said on Monday that it entered in an agreement to license Google Health's AI research model for lung nodule malignancy prediction on CT imaging. 

Aidence will develop, validate and bring this model to the market to support the early and accurate diagnosis of lung cancer and the reduction of unnecessary procedures in screening programs. 
Aidence and Google Health intend to complete an AI application for lung nodule malignancy prediction. 
Per the terms, Google Health will provide its scientific expertise. 
Aidence will further develop the model into a solution for clinical practice and bring it to market, complying with relevant data privacy requirements and regulatory standards. 
The development of this AI application is a statement of intent and no regulatory market applications have been made and no orders for sale are being taken.